Tango Therapeutics Inc. (TNGX) plummeted 10.11% during intraday trading on Friday, as the stock faced significant selling pressure.
The sharp decline followed a series of analyst rating actions, most notably Piper Sandler's downgrade of the stock to Neutral from Overweight, despite simultaneously raising its price target to $24 from $16. Other analyst moves included Leerink Partners raising its target price to $55 from $28 and Mizuho increasing its target to $30 from $20.
The market reaction suggests that the downgrade in rating from Piper Sandler outweighed the positive target price adjustments from other firms, reflecting a shift in sentiment towards the biotechnology company's near-term prospects.
Comments